Can you be specific about the challenges encountered in persons who have been treated with a fixed dose of carbidopa/levodopa (CD/LD) and begin to show signs of therapeutic resistance, manifested by increasing “Off times” and/or suboptimal response?

Can you be specific about the challenges encountered in persons who have been treated with a fixed dose of carbidopa/levodopa (CD/LD) and begin to show signs of therapeutic resistance, manifested by increasing “Off times” and/or suboptimal response?

Can you be specific about the challenges encountered in persons who have been treated with a fixed dose of carbidopa/levodopa (CD/LD) and begin to show signs of therapeutic resistance, manifested by increasing “Off times” and/or suboptimal response?


Created by

CMEducation Resources iQ&A Parkinson’s Disease (PD) Medical Intelligence Zone

Related Presenters

Laxman Bahroo, DO, FAAN

Laxman Bahroo, DO, FAAN

Associate Professor, Department of Neurology Georgetown University Medical Center Vice Chair of Finance Director, Residency Program Director, Botulinum Toxin Clinic Associate Professor of Neurology Medstar Georgetown University HospitalWashington, D.C.